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ARTICLE
Development of an exon skipping therapy for
X-linked Alport syndrome with truncating
variants in COL4A5
Tomohiko Yamamura1, Tomoko Horinouchi 1, Tomomi Adachi2, Maki Terakawa2, Yutaka Takaoka 3,
Kohei Omachi4, Minoru Takasato 5, Kiyosumi Takaishi2, Takao Shoji6, Yoshiyuki Onishi 6,
Yoshito Kanazawa6, Makoto Koizumi6, Yasuko Tomono7, Aki Sugano3, Akemi Shono1, Shogo Minamikawa 1,
China Nagano1, Nana Sakakibara1, Shinya Ishiko1, Yuya Aoto1, Misato Kamura4, Yutaka Harita 8,
Kenichiro Miura9, Shoichiro Kanda8, Naoya Morisada1, Rini Rossanti1, Ming Juan Ye1, Yoshimi Nozu1,
Masafumi Matsuo10, Hirofumi Kai4, Kazumoto Iijima1 & Kandai Nozu 1✉
Currently, there are no treatments for Alport syndrome, which is the second most commonly
inherited kidney disease. Here we report the development of an exon-skipping therapy using
an antisense-oligonucleotide (ASO) for severe male X-linked Alport syndrome (XLAS). We
targeted truncating variants in exon 21 of the COL4A5 gene and conducted a type IV collagen
α3/α4/α5 chain triple helix formation assay, and in vitro and in vivo treatment efficacy
evaluation. We show that exon skipping enabled trimer formation, leading to remarkable
clinical and pathological improvements including expression of the α5 chain on glomerular
and the tubular basement membrane. In addition, the survival period was clearly prolonged in
the ASO treated mice group. This data suggests that exon skipping may represent a pro-
mising therapeutic approach for treating severe male XLAS cases.
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A lport syndrome (AS) is a progressive inherited nephritisaccompanied by sensorineural loss of hearing and ocularabnormalities. AS develops because of pathogenic variants
in one of the three type IV collagen encoding genes, COL4A3,
COL4A4, and COL4A51,2. These three genes encode type IV
collagen α3–α5 chains (α3(IV)–α5(IV)), respectively, and those
chains assemble to form triple helix structures (α345(IV)) that
combine in the glomerular basement membrane (GBM). For-
mation of these triple helix structures is disrupted when an
abnormality occurs in one of the three α chains, and this causes
AS3. AS is divided into three groups according to the inheritance
modes: X-linked Alport syndrome (XLAS), autosomal recessive
AS, and autosomal dominant AS. XLAS is caused by pathogenic
variants in the COL4A5 gene and according to the character of
the X-linked disease, male XLAS cases show much severer phe-
notypes and develop end-stage renal disease (ESRD) during their
20s and 30s4–6. There is currently no radical therapy for this
disease and treatment with nephron-protective drugs only delays
progression to ESRD. For example, angiotensin-converting
enzyme inhibitors can remarkably delay the development of
ESRD by ~10 years7. However, male XLAS cases show a strong
genotype–phenotype correlation and patients possessing trun-
cating mutations still show severe phenotypes and develop ESRD
around the age of 204–6. Therefore, the development of new
treatments for cases with truncating variants is needed urgently.
Antisense oligonucleotides (ASOs) have been successfully used
to treat various inherited diseases, including Nusinersen for spinal
muscular atrophy (SMA), Eteplirsen for Duchenne muscular
dystrophy (DMD), Mipomersen for hypercholesterolemia, and
Inotersen for amyloidosis. We recently published data showing
that COL4A5 gene splice site mutations with an in-frame deletion
at the transcript level showed good renal prognosis and ESRD
developed after 9 years when compared with the out-of-frame
deletion group8. Furthermore, we also reported a 47-year-old
male with a deletion of 105 bp at the transcript level because of a
splice site mutation, who had still not developed ESRD9. These
data prompted us to develop exon-skipping therapy for male
XLAS cases with truncation mutations. The COL4A5 gene
(NM_000495) consists of 51 exons with 44 of these exons
belonging to the collagenous domain (exons 3–46). Among these
44 exons, 35 exons have nucleotide numbers that are a multiple of
3 (Supplementary Table 1). When patients have truncating
mutations in one of these exons, exon skipping can shift the
truncation to a non-truncating mutation, that is, in-frame dele-
tion mutations that can delay the development of ESRD in AS.
This therapy of exon skipping by ASO for genetic diseases was
first reported by our group in 1995 for DMD10. Here, we
attempted exon-skipping therapy using an ASO for a truncating
variant in exon 21 (84 bp) of the COL4A5 gene.
Results
Split luciferase-based trimer formation of the α345(IV) proteins
assay. We have established the split nanoluciferase (NanoLuc)
complementation system for examining the formation of the α345
(IV) trimer11. COL4A5 plasmids for two truncating variants in
exon 21, c.1350_1351delAT (p.Ile450Metfs*2) and c.1411C > T
(p.Gln471*), exon 21 deletion (c.1340_1423del84bp (Δexon 21))
and the wild-type COL4A5 were generated and examined.
Although both truncating variants (p.Ile450Metfs*2 and
p.Gln471*) in exon 21 failed to form trimers in cells and super-
natants, the product of Δexon21 was able to form a trimer (Fig. 1).
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Fig. 1 Split luciferase-based trimer formation of the α345(IV) protein assay. Although both truncating variants, p.Ile450Metfs*2 (I450fs) and p.Gln471*
(Q471X) in exon 21, failed to construct trimers, the Δexon21 variant formed trimers in both cells (a) and supernatant (b). NC: The NanoBiT® Negative
Control Vector, which encodes HaloTag®-SmBiT. Error bars represent the mean ± SE. Source data are provided as a Source Data file. “n= 6” means that
each assay was conducted 6 times.
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3-D structure analysis of the α345(IV) trimer. The 3-D struc-
ture of the α345(IV) trimer was generated using homology
modeling according to our previous research with slight mod-
ifications12. The trimer constructed by p.Gln471* was found to
aggregate, leading to a lower total potential energy. In contrast,
the potential between the wild-type trimer and the trimer formed
by the Δexon21 construct was similar (Fig. 2, Supplementary
Fig. 1).
In vitro exon skipping efficacy evaluation by ASO. The most
effective ASO sequence targeting exon 21 (84 bp) skipping was
determined by our method13. We used 18-mer phosphor-
othioated oligonucleotides consisting of 2′-O-methyl RNA and a
modified nucleic acid (2′-O, 4′-C-ethylene-bridged nucleic acid
(ENA), ASO-ENA)14. Initially, we designed multiple series of
ASOs with slightly different sequences. Each ASO-ENA was
transfected individually into HEK293T cells. The ability of each
ASO to induce exon skipping was examined by comparing the
amount of cDNA with and without exon skipping. Finally, one
ASO-ENA was determined to be the best for molecular therapy.
The sequence of the ASO is: 5′-TggAguccuuuAucAccT-3′; upper
letters: ENA; lower letters: 2′-O-methyl RNA. Exon skipping was
also examined for patient’s urine derived cultured cells (p.
Gln471* in exon 21). The lowest dose (10 nM) was capable of
leading to complete exon 21 skipping (Supplementary Fig. 2).
In vivo exon skipping efficiency evaluation by ASO using a
mouse model. We have recently established a Col4a5 mutant
mouse model with c.1411C > T (p.Arg471*) in exon 21 and this
mutation is equivalent to the nonsense mutation of c.1411C > T
(p.Gln471*) of human COL4A515. For this model, we initiated
subcutaneous treatment with 50 mg/kg of ASO-ENA or vehicle
(saline) for mutant mice (n= 6 for vehicle and n= 5 for ASO)
and with vehicle for wild-type mice (n= 3). The frequency of
administration was twice a week from 4 to 6 weeks of age and
once a week from 7 to 20 weeks of age. Mice were sacrificed at
21 weeks of age and samples were harvested. The transcripts
extracted from each mouse kidney showed clear exon 21 skipping
for only mice that received ASO treatment (Supplementary
Fig. 3). Immunofluorescence analysis revealed that α5(IV) was
completely negative for the vehicle group but was expressed
clearly on tubular basement membranes and even on the GBM,
although expression is not linear but partial on GBM for the ASO
group (Fig. 3; green shows α5(IV) and red shows WT1 as a
podocyte marker). In addition, expression of α3(IV) and α4(IV)
were observed in the ASO group with the same expression pattern
of α5(IV), indicating that a collagen IV alpha345 trimer con-
structed after exon skipping is secreted from podocytes into the
GBM (Supplementary Fig. 4). Pathological evaluation by light
microscopy for hematoxylin and eosin (HE) staining revealed
inflammatory cell infiltration to the interstitial area in the vehicle
treated group; however, wild-type and the ASO-treated groups
remained almost normal in the interstitial region (Fig. 4a–c).
Masson-Trichrome staining revealed interstitial fibrosis in the
vehicle treated group but not in the wild-type and ASO-treated
groups (Fig. 4d–f). With periodic acid methenamine silver (PAM)
staining, global sclerosis was observed in most of the glomerulus
in the vehicle treated group but not in the wild-type and ASO-
treated groups (Fig. 4g–i). Although ASO-treated mice showed
mild irregularity of the GBM when examined by electron
microscopy, they did not show severe thickening with lamellation
as observed for the vehicle treated group (Fig. 4j–l). Clinical
parameters showed no noticeable differences in the body weight
(Fig. 5a). However, the urinary albumin creatinine ratio was
remarkably suppressed in the ASO-treated group when compared
with that of the vehicle treated group (Fig. 5b). At 21 weeks of
age, serum BUN and creatinine levels were remarkably low in the
ASO-treated group when compared with that of the vehicle
treated group (Fig. 5c, d). In addition, to confirm that survival
time by this therapy was prolonged, we compared the survival
time between ASO or vehicle (saline) treated mutant mice (n= 8
for vehicle and ASO groups) and vehicle treated wild-type mice
(n= 6). The results showed that the survival time was sig-
nificantly prolonged in the ASO-treated group when compared
with that of the other two groups (Fig. 5e). In conclusion, we have
successfully shown the efficacy of ASO treatment with
clinical–pathological findings for XLAS with truncating mutation
using an animal model.
In vivo drug delivery evaluation of ASO using a mouse model.
To confirm the uptake of ASO in kidney tissue, especially
podocytes, we administrated a single dose of ASO-ENA tagged by
cyanine 3 to both wild-type and mutant mice, and sacrificed the
mice 24 h and 2 weeks following dosage. The results clearly
showed ASO-ENA in podocytes and tubular epithelial cells of
every specimen (Supplementary Fig. 5).
Discussion
Recently, ASO therapies have gained attention as an approach to
treat various diseases16. Oligonucleotides are short nucleic acids
that usually consist of 13–25 nucleotides and are designed to
hybridize with DNA or RNA specific regions that have com-
plementary sequences and such hybridization changes the
expression level of proteins. Currently, four ASO therapies have
been approved by the Food and Drug Administration (FDA):
Eteplirsen for DMD, Nusinersen for SMA, Mipomersen for
hypercholesterolemia and Inotersen for amyloidosis. In addition,
some drugs are under clinical trials for treating chylomicronemia
syndrome, Huntington’s disease, and hyperlipidemias16. In par-
ticular, Eteplirsen is an ASO that induces exon skipping in the
DMD gene and changes frameshift variants into in-frame var-
iants, which leads to production of functional dystrophin. We
hypothesized that applying this exon skipping therapy for XLAS
would be possible because this disease also shows a strong
genotype-phenotype correlation as observed for DMD. Eteplirsen
has been reported to show weaker activity than expected. A
NC1 domain NC1 domain
a
b d
c
Fig. 2 3-D structure analysis of collagen IV. aWild-type. b, d, p.Gln471* (d
cropped). c Δexon21. Green: α3; blue: α4; and pink: α5. Formation of the
trimer by p.Gln471* was followed by collapse of the whole structure.
Δexon21 formed a similar structure to that of the wild-type trimer. a–c the
same scale, d ×3.5 magnification to confirm the chains.
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reason for this weak activity may be because the majority of the
drug is rapidly filtered into the urine from the glomerulus and
only a small amount of the drug reaches skeletal muscle16. Thus,
developing an ASO for the treatment of kidney diseases seems to
be a very promising, straightforward approach. In this report, we
showed the promising effect of ASO therapy for male XLAS.
Figure 6 shows a schematic describing the possible mechanism of
ASO treatment against XLAS. With truncating variants in
COL4A5, α5(IV) is terminated at the stop codon and the NC1
domain is absent. We have shown here and previously that the
NC domain is important for α345(IV) trimer formation9,11,
because formation is dependent on the association of the NC
domains3,17. Exon-skipping therapy was found to replace the
truncating variant with an in-frame deletion at the transcription
level, and the resulting protein from this therapy formed the
trimer. Thus, this therapy rescued progression of kidney failure in
XLAS. Surprisingly, exon-skipping therapy caused clear α5(IV)
expression on the tubular basement membrane and GBM. We
have reported previously about 29% of the male XLAS cases show
α5(IV) expression on the GBM and show much milder pheno-
types of developing ESRD 13 years later when compared with
cases that have negative α5(IV) expression18. We have also
published data that splice site mutations with in-frame deletions
at the transcription level show later development of ESRD8. These
data provided impetus to develop this therapy for male XLAS
cases and we have successfully proven the extraordinary effect of
an exon 21 truncating variant.
This RNA targeted therapy is theoretically effective for severe
male XLAS cases with truncating variants located in 35 exons in
the collagenous domain with nucleotide numbers that have a
multiple of three (Supplementary Table 1). Although we proved
the remarkable effect of exon-skipping therapy only for exon 21
in this study, it remains unknown whether this therapeutic
approach will be effective for the other 34 exons with nucleotide
numbers that have multiples of three. Our previous study
revealed that there is only a 9-year difference in the renal survival
period between patients with splice site mutations resulting in in-
frame deletions and frameshift transcript8. This is because in
some of the exons in-frame deletions do not show milder phe-
notypes. Regarding exon 21, the renal survival period of the
reported three male cases with estimated exon 21 skipping
(c.1340-2A > G, c.1423+ 1G > A, c.1423+ 1G > T) were over 25
years, over 35 years and 52 years, respectively19–21. In contrast,
the reported three patients with an exon 21 truncating variant
(c.1376delC) reached ESRD at the mean age of 20 and there was a
clear difference between these two groups22. In addition, we
conducted an additional study to prove the substantial renal
rescue effect of exon 21 skipping by a long-term mice study. The
results of this study showed that the survival period was clearly
prolonged in the ASO-treated group (Fig. 5e). In conclusion,
these observations show that exon 21 skipping is effective.
Future alternative efforts require establishing mutant mouse
models for other exons because there are another 34 exons that
could be targeted by an ASO. The most promising candidate to
establish a therapeutic effect evaluation system is a study using
iPS cells. Currently, it is possible to generate podocytes and
kidney organoids23,24. Using this system, we can assess the effect
of each exon skipping and have initiated this effort. We are also
examining whether the α345(IV) trimer is formed for all 35 exons
in an effort to develop drugs for further candidate exons for this
therapy using the NanoLuc system and modeling. Although our
study showed no side effects to the mice, we also have to conduct
good laboratory practice and a safety assessment study before
initiating a clinical trial for exon 21 skipping therapy.
Targeted delivery of the drug to a particular organ is an
important feature of any therapy. Targeting the kidney is
advantageous because most drugs pass through the glomerulus.
Our data showed tagged ENA-ASO was delivered to podocytes
along with tubular epithelial cells, and the ENA-ASO remained in
these cells for at least 2 weeks (Supplementary Fig. 5). This
finding suggests that frequent drug administration can be
avoided.
Our present study has some limitations. Firstly, unfortunately,
we failed to evaluate the protein expression levels of α5(IV) in
ASO-treated mice by western blotting, which may be because of
the quality of the antibody. However, from other results, we
concluded that exon 21 skipping showed a remarkable effect.
Secondly, the exon skipping long-term side effects were not
evaluated. Additionally, long-term ASO effects toward wild-type
mice have not been evaluated. This treatment can cause AS with a
mild phenotype. As a next step, we are planning to conduct long-
term safety evaluation tests on wild-type mice and cynomolgus
monkeys to assess any effects before a starting clinical trial.
In conclusion, we have developed an exon-skipping therapy
that prevents progression of kidney failure in AS. These findings
suggest that exon skipping represents a promising therapeutic
approach for male XLAS cases with truncating mutations.
Methods
Split luciferase-based trimer formation of the α345(IV) proteins assay. For
examining the formation of the α345(IV) trimer, we have established a split
nanoluciferase (NanoLuc) complementation system11. Briefly, split NanoLuc is
composed of a large fragment (LgBiT) and a small fragment (SmBiT) of the
NanoLuc luciferase. Luminescence is observed when the split NanoLuc-tagged
proteins interact with LgBiT and SmBiT. We constructed plasmids for COL4A3,
COL4A4, and COL4A5 containing C-terminal-tagged SmBiT for COL4A3 and
a b
c d
e f
Fig. 3 Type IV collagen α5 chain staining at 21 weeks of age. Green:
Type IV collagen α5 chain. Red: WT1 as a podocyte marker. a Wild-type
mouse treated with the vehicle. b Mutant mouse treated with the vehicle.
c–f Mutant mouse treated with the antisense oligonucleotide (ASO)
(e, f cropped). Type IV collagen α5 chain was completely negative in
the vehicle group (b), but was clearly expressed on the tubular basement
membrane and even on the glomerular basement membrane (GBM);
although, expression was only partial on the GBM (e, f arrows). Scale
bars are 100 μm. Two different researchers from different institutes
conducted the staining, and the expression pattern was identical.
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LgBiT for COL4A5, and those were inserted into the pBiT2.1-C [TK/SmBiT] vector
and pBiT1.1-C [TK/LgBiT] vector, respectively. Following transfection of these
three plasmids into HEK293T cells, luminescence was detected with high sensitivity
from the heterotrimer of α345(IV) but not from the homodimer or heterodimer
expressing cells or supernatant. COL4A5 mutants were generated by mutagenesis.
Primer sequences are shown in Supplementary Table 2. COL4A5 plasmids for two
truncating variants in exon 21, c.1350_1351delAT (p.Ile450Metfs*2), c.1411C > T
(p.Gln471*), and exon 21 deletion (c.1340_1423del84bp (Δexon21)) were gener-
ated. COL4A3-SmBiT, COL4A5-LgBiT, and COL4A4 plasmids were transfected
into HEK293T cells. At 48 h after transfection, the Nano-Glo Live Cell Assay
reagent was added and the luciferase activity in the medium and cells were mea-
sured using a SpectraMax M4 (Molecular Devices, San Jose, CA, USA). All luci-
ferase assays were conducted in CORNING® TypeI Collagen Coated 96-Well Cell
Culture Clear Bottom White plates (Nippi Incorporated). Each assay was con-
ducted six times.
3-D structure analysis of collagen IV. The 3-D structure of the α345(IV) trimer
was generated using homology modeling according to our previous research with
slight modifications as follows12. The amino acid sequences of wild-type human α3
(IV)–α5(IV) were downloaded from the NCBI protein database (Accession Nos.
α3, NP_000082.2; α4, NP_000083.2; α5, and NP_000486.1). The amino acid
sequences of c.1411C > T (p.Gln471*) and c.1340_1423del84bp (Δexon21) mutant
α5(IV) were prepared from the amino acid sequences of wild-type α5(IV). Upon a
BLAST search against the Protein Data Bank (PDB), PDB IDs 3HQV, 5NB0, 5NB1,
and 5NAZ were identified as templates for the triple helical region and the NC1
domains of α3(IV)–α5(IV), respectively. Since 3HQV contains only alpha carbon
atoms, the alphabuild.svl script of the Molecular Operating Environment (MOE)
software (Chemical Computing Group, Quebec, Canada) was used to generate the
coordinates of the remaining atoms. The 3-D structures of wild-type and mutant
trimers were generated using the homology modeling function in the MOE soft-
ware. The resulting structures were subjected to structural optimization by
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Fig. 4 Light microscopic and electron microscopic findings at 21 weeks. a–c Hematoxyline and eosin staining for wild-type (a), vehicle treated (b), and
antisense oligonucleotide (ASO) treated (c) mice. Magnification, ×40. d–f Masson-Trichrome staining of wild-type (d), vehicle treated (e), and ASO-
treated (f) mice. Magnification, ×40. g–i Periodic acid methenamine silver (PAM) staining of wild-type (g), vehicle treated (h), and ASO-treated (i) mice.
Magnification, ×160. j–l Electron microscopic (EM) images of wild-type mouse treated with vehicle (j), mutant mouse treated with vehicle (k), and mutant
mouse treated with the antisense oligonucleotide (l). With pathological evaluation by light microscopy for hematoxylin and eosin staining, inflammatory
cell filtration to the interstitial area was observed in the vehicle treated group; however, wild-type (WT) and ASO-treated groups remained essentially
normal in the glomerulus and interstitial region (a–c). Masson-Trichrome staining revealed interstitial fibrosis in the vehicle treated group but not in the
WT and ASO-treated groups (d–f). With periodic acid methenamine silver (PAM) staining, global sclerosis was observed in most of the glomerulus in the
vehicle treated group but not in the WT and ASO-treated groups (g–i). With EM, although ASO-treated mice showed mild irregularity of the glomerular
basement membrane (GBM) (arrows), they did not show severe thickening with lamellation (L) as was observed in the vehicle treated group (k,
arrowheads). Scale bars are 100 μm in (a–f), 20 μm in (g–i) and 2 μm in (j–l). Each staining was conducted once for all samples and all samples in the
treatment group show identical staining patterns.
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GROMACS version 5.1.5 (http://manual.gromacs.org/documentation/5.1-current/
index.html)12. The AMBER99SB-ILDN force field was used for all simulations25.
To reduce the computational cost, the protein was solvated in a generalized Born
implicit solvent model instead of explicit solvent, as described in our previous
studies26,27. To shorten the real-time required for MM/MD calculation steps of
structural analysis27, we used 94319.53 Node*Hour computational resources on
the K supercomputer for structural optimization of wild-type and mutant collagen
IV trimers (α3–α5). As for financial costs, the total charge of the K supercomputer
was 1,370,463 yen (charge: 14.53 yen per node hour). Production runs of molecular
dynamics simulations were carried out using 144 nodes on the supercomputer K
(RIKEN AICS in Japan).
In vitro exon skipping efficiency evaluation by ASO. The most efficient ASO
sequence was determined by the method reported from our group13. First, we
designed multiple series of ASOs with slightly different sequences. We used 18-mer
phosphorothioated oligonucleotides consisting of 2′-O-methyl RNA and modified
nucleic acids (2′-O, 4′-C-ethylene-bridged nucleic acid (ENA), ASO-ENA)14. Each
ASO-ENA was transfected individually into HEK293T cells by using the Lipo-
fectamine RNAiMAX Transfection Reagent® (Thermo Fisher Scientific), and the
mRNA was analyzed by reverse transcription polymerase chain reaction (RT-PCR).
Twenty-four hours later, total RNA was extracted from cells and cDNA was syn-
thesized by using the SuperPrep® Cell lysis & RT kit for qPCR (TOYOBO). PCR was
performed with a forward primer located in exon 19 and a reverse primer located in
exon 23. Primer sequences are shown in Supplementary Table 2. PCR products were
analyzed by LabChip™ (PerkinElmer Co., Ltd.) followed by Sanger sequencing.
In vivo exon skipping efficiency evaluation by ASO using a mouse model.
We have recently established a Col4a5 mutant mouse model with c.1411C > T
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(p.Arg471*) in exon 21 and this mutation is equivalent to the nonsense mutation
of c.1411C > T (p.Gln471*) found in human COL4A5 (developed by Axcelead
Drug Discovery Partners, Kanagawa, Japan)15. This male mouse showed protei-
nuria and hematuria. The pathological finding follows human AS with diffuse
GBM lamellation. These observations are consistent with the clinical and patho-
logical features of patients with AS. These mice develop ESRD at the median age of
28 weeks. For this model, we started subcutaneous treatment with 50 mg/kg of
ASO-ENA or vehicle (saline) for mutant mice (n= 6 for vehicle and n= 5 for
ASO) and with vehicle for wild-type mice (n= 3). We started the treatment twice a
week from 4 to 6 weeks of age and once a week from 7 to 20 weeks of age. We
sacrificed mice at 21 weeks of age and harvested samples. All mice were kept in
a regular 12 h light–12 h dark cycle under specific pathogen free conditions at
22–25 °C. We measured body weight every week and the urine albumin creatinine
ratio once every 3 weeks. We also measured serum albumin, blood urea nitrogen
(BUN) and creatinine levels at 21 weeks of age. For pathological evaluation, we
observed light microscopic findings, electron microscopic findings and conducted
immunofluorescence analysis for α3/α4/α5(IV) (129/b42/H53, Shigei Medical
Research Institute, Okayama, Japan)28, and these antibodies were used at 1:50, 1:50,
and 1:100 dilutions in blocking buffer, respectively. Some were counter stained with
the WT1 protein at a 100× dilution in blocking buffer (podocyte marker, Abcam
ab89901, Cambridge, UK). In addition, to prove survival by exon 21 skipping was
prolonged, we conducted subcutaneous injections with 50 mg/kg of ASO-ENA or
vehicle (saline) for mutant mice (n= 8 for both vehicle and ASO) and with vehicle
for wild-type mice (n= 6). Weekly administration was continued until 50% of
vehicle treated mutant mice died.
In vivo drug delivery evaluation of ASO using a mouse model. For this model,
we administrated a single dose of 50 mg/kg of ASO-ENA tagged with cyanine 3 at
6 weeks of age. We sacrificed mice 24 h (n= 2 for wild-type and n= 3 for mutant)
or 2 weeks (n= 2 for both wild-type and mutant) after administration and har-
vested samples. All mice were kept in a regular 12 h light–12 h dark cycle under
specific pathogen free conditions at 22 °C. We conducted immunofluorescence
analysis for the WT1 protein at a 100× dilution in blocking buffer (podocyte
marker, Abcam ab89901, Cambridge, UK) and observed uptake of ASO-ENA in
kidney tissue.
Statistical analysis. For analysis of clinical parameters, all data are presented as
means ± standard errors. The significance of differences between two groups was
assessed using the Welch’s t test. Differences with P values of less than 0.05 were
considered statistically significant. Those were calculated by REDPOST (SAS
institute Inc., Cary, NC, USA). For survival period analysis, the significance of
differences between groups was assessed using the Log-rank test. Differences with
P values of less than 0.05 were considered statistically significant.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Data that support the findings of this study are available from the corresponding
author upon reasonable request. The source data underlying Figs. 1a, b, 5a–e, and
Supplementary Fig. 1 as well as Supplementary Table 3 are provided as a Source
Data file.
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